Receptos doubles up with RPC1063 in UC

Receptos Inc. (NASDAQ:RCPT) on Monday reported that RPC1063 met the primary endpoint in a Phase II trial in a second hot disease space, ulcerative colitis (UC), and now needs to think strategically about its partnering options.

In the 199-patient TOUCHSTONE study, clinical remission was observed at week 8 in 16.4% of patients receiving 1 mg doses of the selective sphingosine 1-phosphate receptor ( S1PR1; S1P1; EDG1) modulator, compared to 6.2% of those receiving placebo (p<0.05). ...